Skip to main content
JAMA Network logoLink to JAMA Network
. 2019 Dec 19;6(2):302. doi: 10.1001/jamaoncol.2019.6210

Errors in Table

PMCID: PMC6990827  PMID: 31855228

In the Original Investigation by Yoshino et al titled “Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial,”1 published online September 12, 2019, and printed November 14, 2019, a column head in Table 2 was misspelled. The correct spelling is mFOLFOX6. There was also a data error in Table 2. This article was corrected online. This article was also corrected on November 14, 2019, to change to CC-BY-NC-ND open access status.2

References

  • 1.Yoshino T, Yamanaka T, Oki E, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial [published online September 12, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.2572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Status change to open access after publication. JAMA Oncol. 2019;5(11):1643. doi: 10.1001/jamaoncol.2019.5334 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Oncology are provided here courtesy of American Medical Association

RESOURCES